LYPLA2

Across TCGA pan-cancer cohorts, LYPLA2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of LYPLA2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where LYPLA2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types LYPLA2 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where LYPLA2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LYPLA2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	IV	−0.326	<.001	11	view →
LUAD	Female	II,III,IV	+0.513	<.001	9	view →
HNSC	Male	All	−0.205	<.001	8	view →
PDAC	Male	All	+0.296	<.001	6	view →
LSCC	Male	II,III,IV	+0.162	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

LYPLA2–CCRCC

Open the CCRCC breakdown →